We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
21 Jun 2021 - 24 Jun 2021

Vitamin D Deficiency Linked to Metabolic Changes in Lupus Patients

By LabMedica International staff writers
Posted on 15 Apr 2021
Print article
Image: Lower vitamin D levels are associated with metabolic syndrome and insulin resistance in systemic lupus (Photo courtesy of Nikki Yelton, RD)
Image: Lower vitamin D levels are associated with metabolic syndrome and insulin resistance in systemic lupus (Photo courtesy of Nikki Yelton, RD)
Systemic lupus erythematosus (SLE), is the most common type of lupus. SLE is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels.

Metabolic syndrome is a cluster of conditions that occur together, increasing the risk of heart disease, stroke and type 2 diabetes. These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels. Metabolic syndrome is increasingly common, and up to one-third of adults in the USA have it.

A large team of immunologists and their international colleagues working with the University of Birmingham (Birmingham, UK) examined vitamin D levels in 1,163 patients with SLE across 33 centers in 11 countries. Clinical, laboratory and therapeutic data were collected. Vitamin D level was defined according to tertiles based on distribution across this cohort, which were set at T1 (10–36 nmol/L), T2 (37–60 nmol/L) and T3 (61–174 nmol/L). Metabolic syndrome was defined according to the 2009 consensus statement from the International Diabetes Federation. Insulin resistance was determined using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) model. Linear and logistic regressions were used to assess the association of variables with vitamin D levels.

The team reported that of the 1,847 patients, 1,163 (63%) had vitamin D measured and 398 (34.2%) subjects were in the lowest 25(OH)D tertile. Metabolic syndrome was present in 286 of 860 (33%) patients whose status could be determined. Patients with lower 25(OH)D were more likely to have metabolic syndrome and higher HOMA-IR. The metabolic syndrome components, hypertension, hypertriglyceridemia and decreased high-density lipoprotein (HDL) were all significantly associated with lower 25(OH)D. Increased average glucocorticoid exposure was associated with higher insulin resistance.

John A. Reynolds, MD, a Consultant Rheumatologist and a senior author of the study. said, “Our results suggest that co-existing physiological abnormalities may contribute to long-term cardiovascular risk early on in systemic lupus erythematosus. We found a link between lower levels of vitamin D and metabolic syndrome and insulin resistance.”

The authors concluded that metabolic syndrome and insulin resistance are associated with lower vitamin D in patients with SLE. Further studies could determine whether vitamin D repletion confers better control of these cardiovascular risk factors and improve long-term outcomes in SLE. The study was published originally published on February 8, 2021 in the journal Rheumatology.

Related Links:
University of Birmingham

Gold Supplier
Tumor Marker Control
Tumor Marker Control
New
Gold Supplier
SARS-CoV2 Antigen Rapid Test
SARS-CoV2 Antigen Rapid Test
New
COVID-19 Test
CLART COVID-19
New
SARS-CoV-2 IgA Detection Kit
EIAgen SARS-CoV-2 IgA Kit

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Illustration

Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028

The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.